EDMONTON, ALBERTA -- (Marketwire) -- 11/21/12 -- Innovotech Inc. (TSX VENTURE:IOT) announced its unaudited financial and operational results for the quarter ended September 30, 2012.

Highlights:

--  Strongest quarter in 2012 for contract research revenue. 
--  Advanced antimicrobial coating and wound dressing attracts industry
    leaders because of unique properties 
--  Overcame supply problems with InnovoSCEPT susceptibility tests and
    joined full scale efforts of marketing partner to introduce the new
    technology to the veterinary market

"The Company showed the strongest revenues of the year in contract research during the quarter" said Ken Boutilier, President of Innovotech. "We attribute this to our marketing efforts including the Biofilm Workshop held for the U.S. FDA and clients earlier this year."

"In addition, we have seen strong interest from medical device companies for our first antimicrobial coating from the AgreGuard family. Response to this unique product has been good, as rates of hospital-acquired infections are increasing and hospitals are seeking better antimicrobial products from medical device companies" says Boutilier.

Company has helped resolve previously disclosed problems with the manufacturing of InnovoSCEPT biofilm susceptibility tests and is working with its distribution partner to introduce the new technology to the veterinary market.

Financial Summary

----------------------------------------------------------------------------
                      Three-month   Three-month    Nine-month    Nine-month 
($)                  period ended  period ended  period ended  period ended 
                    September 30, September 30, September 30, September 30, 
                             2012          2011          2012          2011 
----------------------------------------------------------------------------
Revenues                  342,031       393,971       644,860       825,428 
----------------------------------------------------------------------------
G&A                       270,165       335,876       816,862       890,200 
----------------------------------------------------------------------------
R&D                       264,037       253,415       817,731       760,674 
----------------------------------------------------------------------------
Net loss                 (235,302)     (189,198)   (1,075,354)     (843,049)
----------------------------------------------------------------------------
Share Price                     -             -           .35           .70 
----------------------------------------------------------------------------
Cash position                   -             -       242,633       544,062 
----------------------------------------------------------------------------

Revenues

In the three-month period ended September 30, 2012, total revenues were $342,031 (2011 - $393,970; 2010 - $425,051). This included contract research revenue of $285,834 (2011 - $327,614; 2010 - $395,332) and product sales of $56,197 (2011 - $66,356; 2010 - $29,719). Contract research revenue has improved over the course of the year but did not reach the Q3 2011 level. Low product sales were due to delays in manufacturing of InnovoSCEPT(TM) veterinary tests. In the nine-month period ended September 30, 2012, total revenues were $644,860 (2011 - $825,428; 2010 - $1,287,709).

General and Administrative Expense

In the three-month period ended September 30, 2012, general and administrative expense, including stock based compensation expense and allocated amortization expense, was $270,165 (2011 - $335,876). In the nine-month period ended September 30, 2012, general and administrative expenses were $816,862 (2011 - $890,200). The reduction of G&A expenses is a result of selective staff reduction measures taken during the year.

Research and Development

In the three-month period ended September 30, 2012, research and development expense was $264,037 (2011 - $253,415). The cost was partially offset by various grants of $129,056 (2011 - $118,374). In the nine-month period ended September 30, 2012, research and development expense was $817,731 (2011 - $760,674). Increased research and development costs are largely due to costs associated with the regulatory package being developed for Agress® for the EPA submission and development of improved manufacturing methods; and for costs incurred in the development of the AgreGuard family of products.

Liquidity and Capital Resources

At September 30 2012, the Company had $242,633 in cash compared to $459,275 at December 31, 2011. Slower than anticipated recovery of contract research revenue combined with manufacturing delays of InnovoSCEPT(TM) veterinary tests have contributed to a decrease in cash reserves. The company has taken active measures to increase contract research and to accelerate product sales revenue.

Innovotech's third quarter 2012 Financial Statements and Management's Discussion and Analysis will be filed on The System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com

About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are organized communities of microorganisms that exist in virtually every natural environment and are responsible for a host of diseases in human health, animal health and agriculture. There are few products or regulatory standards, aside from those of Innovotech, designed specifically for biofilm-forming organisms.

Innovotech has a broad range of products that address the issue of biofilms within a number of different industries, including commercially available products in three market segments; the MBEC Assay(TM), bioFILM PA(TM), InnovoSCEPT-Human and InnovoSCEPT-Veterinary tests. The MBEC Assay(TM) is a high throughput biofilm growth device that was recently approved as an ASTM International standard. bioFILM PA(TM) and InnovoSCEPT-Human are the first diagnostic tests to assist physicians in the selection of the most effective antibiotic treatment for patients with biofilm-based chronic infections, while the InnovoSCEPT veterinary tests are designed to determine the most effective antibiotic treatment for chronic infections in both large and small animals.

Innovotech also has two products in advanced stages of development; Agress® is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections and AgreGuard(TM) is a unique antimicrobial for coating medical devices such as catheters.

Blog: www.cf-test.ca

Twitter: www.twitter.com/innovotech

Facebook: www.facebook.com/innovotech

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.